Aromatic hydrocarbon receptor inhibits lysophosphatidic acid-induced vascular endothelial growth factor-A expression in PC-3 prostate cancer cells

Biochemical and Biophysical Research Communications

Volumn 437, Issue 3, 2013, Pages 440-445

  Wu, Pei Yi ^a   Lin, Yueh Chien ^a   Lan, Shun Yan ^a   Huang, Yuan Li ^b   Lee, Hsinyu ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

Author keywords

AHR; HIF 1; LPA; VEGF

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; LYSOPHOSPHATIDIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; VANADIC ACID; VASCULOTROPIN A;

ARTICLE; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

AHR; HIF-1; LPA; VEGF;

ANGIOGENESIS INDUCING AGENTS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; CELL LINE, TUMOR; HEK293 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYSOPHOSPHOLIPIDS; MALE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RECEPTORS, ARYL HYDROCARBON; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880965149     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.098     Document Type: Article

References (50)

1. Greenlee R.T., Murray T., Bolden S., Wingo P.A. Cancer statistics, 2000. CA Cancer J. Clin. 2000, 50:7-33.
2. Denmeade S.R., Lin X.S., Isaacs J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996, 28:251-265.
3. Huggins C. Endocrine-induced regression of cancers. Cancer Res. 1967, 27:1925-1930.
4. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1:34-45.
5. Grossmann M.E., Huang H., Tindall D.J. Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl. Cancer Inst. 2001, 93:1687-1697.
6. Xu Y., Gaudette D.C., Boynton J.D., Frankel A., Fang X.J., Sharma A., Hurteau J., Casey G., Goodbody A., Mellors A., et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin. Cancer Res. 1995, 1:1223-1232.
7. Mills G.B., Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 2003, 3:582-591.
8. Eichholtz T., Jalink K., Fahrenfort I., Moolenaar W.H. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J. 1993, 291(Pt 3):677-680.
9. Westermann A.M., Havik E., Postma F.R., Beijnen J.H., Dalesio O., Moolenaar W.H., Rodenhuis S. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann. Oncol. 1998, 9:437-442.
10. Noguchi K., Herr D., Mutoh T., Chun J. Lysophosphatidic acid (LPA) and its receptors. Curr. Opin. Pharmacol. 2009, 9:15-23.
11. Qi C., Park J.H., Gibbs T.C., Shirley D.W., Bradshaw C.D., Ella K.M., Meier K.E. Lysophosphatidic acid stimulates phospholipase D activity and cell proliferation in PC-3 human prostate cancer cells. J. Cell. Physiol. 1998, 174:261-272.
12. Andela V.B. Re S. S. Virtanen et al., Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002;62: 2708-14 - Re K. Sawada et al., Alendronate inhabits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res 2002;62: 6015-20. Cancer Res. 2004, 64:2934-2935.
13. Raj G.V., Sekula J.A., Guo R., Madden J.F., Daaka Y. Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB. Prostate 2004, 61:105-113.
14. Hao F., Tan M., Xu X., Han J., Miller D.D., Tigyi G., Cui M.Z. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38 alpha. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2007, 1771:883-892.
15. Rodriguez-Jimenez F.J., Moreno-Manzano V. Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective. Cell. Mol. Life Sci. 2012, 69:519-534.
16. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59:5830-5835.
17. Lee J., Park S.Y., Lee E.K., Park C.G., Chung H.C., Rha S.Y., Kim Y.K., Bae G.U., Kim B.K., Han J.W., Lee H.Y. Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin. Cancer Res. 2006, 12:6351-6358.
18. Sommer R.J., Sojka K.M., Pollenz R.S., Cooke P.S., Peterson R.E. Ah receptor and ARNT protein and mRNA concentrations in rat prostate: effects of stage of development and 2,3,7, 8-tetrachlorodibenzo-p-dioxin treatment. Toxicol. Appl. Pharmacol. 1999, 155:177-189.
19. Kashani M., Steiner G., Haitel A., Schaufler K., Thalhammer T., Amann G., Kramer G., Marberger M., Scholler A. Expression of the aryl hydrocarbon receptor (AhR) and the aryl hydrocarbon receptor nuclear translocator (ARNT) in fetal, benign hyperplastic, and malignant prostate. Prostate 1998, 37:98-108.
20. Fritz W.A., Lin T.M., Peterson R.E. The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates. Carcinogenesis 2008, 29:1077-1082.
21. Fritz W.A., Lin T.M., Cardiff R.D., Peterson R.E. The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis 2007, 28:497-505.
22. Lin C.E., Chen S.U., Lin C.C., Chang C.H., Lin Y.C., Tai Y.L., Shen T.L., Lee H. Lysophosphatidic acid enhances vascular endothelial growth factor-C expression in human prostate cancer PC-3 cells. PLoS One 2012, 7:e41096.
23. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., von Kriegsheim A., Hebestreit H.F., Mukherji M., Schofield C.J., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
24. Greer S.N., Metcalf J.L., Wang Y., Ohh M. The updated biology of hypoxia-inducible factor. EMBO J. 2012, 31:2448-2460.
25. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 2002, 277:38205-38211.
26. Segrelles C., Ruiz S., Santos M., Martinez-Palacio J., Lara M.F., Paramio J.M. Akt mediates an angiogenic switch in transformed keratinocytes. Carcinogenesis 2004, 25:1137-1147.
27. Befani C.D., Vlachostergios P.J., Hatzidaki E., Patrikidou A., Bonanou S., Simos G., Papandreou C.N., Liakos P. Bortezomib represses HIF-1alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J. Mol. Med. (Berl) 2012, 90:45-54.
28. Park K.Y., Lee H.J., Jeong S.J., Lee H.J., Kim H.S., Kim S.H., Lim S., Kim H.C., Lu J., Kim S.H. 1,2,3,4,6-Penta-O-galloly-beta-d-glucose suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and signaling in LNCaP prostate cancer cells. Biol. Pharm. Bull. 2010, 33:1835-1840.
29. Manohar S., Padgaonkar A., Jalota-Badhwar A., Sonawane V., Rathos M., Kumar S., Joshi K. A novel inhibitor of hypoxia-inducible factor-1alpha P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells. BMC Cancer 2011, 11:338.
30. Jiang B.H., Jiang G., Zheng J.Z., Lu Z., Hunter T., Vogt P.K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001, 12:363-369.
31. Du J., Sun C., Hu Z., Yang Y., Zhu Y., Zheng D., Gu L., Lu X. Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling. PLoS One 2010, 5:e15940.
32. Singla A., Kumar A., Priyamvada S., Tahniyath M., Saksena S., Gill R.K., Alrefai W.A., Dudeja P.K. LPA stimulates intestinal DRA gene transcription via LPA2 receptor, PI3K/AKT, and c-Fos-dependent pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302:G618-627.
33. Yang K., Zheng D., Deng X., Bai L., Xu Y., Cong Y.S. Lysophosphatidic acid activates telomerase in ovarian cancer cells through hypoxia-inducible factor-1alpha and the PI3K pathway. J. Cell. Biochem. 2008, 105:1194-1201.
34. Xie Y., Gibbs T.C., Meier K.E. Lysophosphatidic acid as an autocrine and paracrine mediator. Biochim. Biophys. Acta 2002, 1582:270-281.
35. Ke Q., Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 2006, 70:1469-1480.
36. Sandau K.B., Fandrey J., Brune B. Accumulation of HIF-1alpha under the influence of nitric oxide. Blood 2001, 97:1009-1015.
37. Saunders J.A., Rogers L.C., Klomsiri C., Poole L.B., Daniel L.W. Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells. Free Radic. Biol. Med. 2010, 49:2058-2067.
38. Chandel N.S., Maltepe E., Goldwasser E., Mathieu C.E., Simon M.C., Schumacker P.T. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc. Natl. Acad. Sci. 1998, 95:11715-11720.
39. Guzy R.D., Schumacker P.T. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp. Physiol. 2006, 91:807-819.
40. Laderoute K.R., Amin K., Calaoagan J.M., Knapp M., Le T., Orduna J., Foretz M., Viollet B. 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol. Cell. Biol. 2006, 26:5336-5347.
41. Hoek T.L.V., Becker L.B., Shao Z.-H., Li C.-Q., Schumacker P.T. Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion. Circ. Res. 2000, 86:541-548.
42. Fleming C.R., Billiard S.M., Di Giulio R.T. Hypoxia inhibits induction of aryl hydrocarbon receptor activity in topminnow hepatocarcinoma cells in an ARNT-dependent manner. Comp. Biochem. Physiol. C: Toxicol. Pharmacol. 2009, 150:383-389.
43. Prasch A.L., Andreasen E.A., Peterson R.E., Heideman W. Interactions between 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and hypoxia signaling pathways in Zebrafish: hypoxia decreases responses to TCDD in Zebrafish embryos. Toxicol. Sci. 2004, 78:68-77.
44. Jensen K.A., Luu T.C., Chan W.K. A truncated Ah receptor blocks the hypoxia and estrogen receptor signaling pathways: a viable approach for breast cancer treatment. Mol. Pharm. 2006, 3:695-703.
45. Gao N., Ding M., Zheng J.Z., Zhang Z., Leonard S.S., Liu K.J., Shi X., Jiang B.-H. Vanadate-induced expression of hypoxia-inducible factor 1α and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J. Biol. Chem. 2002, 277:31963-31971.
46. Fritz W.A., Lin T.-M., Safe S., Moore R.W., Peterson R.E. The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Biochem. Pharmacol. 2009, 77:1151-1160.
47. Thackaberry E.A., Gabaldon D.M., Walker M.K., Smith S.M. Aryl hydrocarbon receptor null mice develop cardiac hypertrophy and increased hypoxia-inducible factor-1α in the absence of cardiac hypoxia. Cardiovasc. Toxicol. 2002, 2:263-273.
48. Wang T., Wyrick K.L., Meadows G.G., Wills T.B., Vorderstrasse B.A. Activation of the aryl hydrocarbon receptor by TCDD inhibits mammary tumor metastasis in a syngeneic mouse model of breast cancer. Toxicol. Sci. 2011, 124:291-298.
49. Liu S., Abdelrahim M., Khan S., Ariazi E., Jordan V.C., Safe S. Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells. Biol. Chem. 2006, 387:1209-1213.
50. Fritz W.A., Lin T.M., Safe S., Moore R.W., Peterson R.E. The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Biochem. Pharmacol. 2009, 77:1151-1160.